Spots Global Cancer Trial Database for triple negative breast cancer
Every month we try and update this database with for triple negative breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer | NCT04947189 | Triple Negative... | Seviteronel-D (... Docetaxel | 18 Years - | St Vincent's Hospital, Sydney | |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | NCT03205176 | Malignant Solid... Lymphoma Ovarian Cancer Breast Cancer Pancreatic Canc... Prostate Cancer | AZD5153 Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | NCT02807844 | Triple Negative... Pancreatic Carc... Melanoma Endometrial Car... | MCS110 PDR001 | 18 Years - | Novartis | |
| TT-702 in Patients With Advanced Solid Tumours. | NCT05272709 | Advanced Solid ... | TT-702 Darolutamide | 16 Years - | Cancer Research UK | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | NCT03797326 | Advanced Solid ... Triple Negative... Ovarian Cancer Gastric Cancer Colorectal Canc... Glioblastoma Biliary Tract C... Pancreatic Canc... | Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | NCT06440005 | Cancer Advanced Cancer Locally Advance... Metastatic Soli... Triple Negative... Pancreas Cancer Pancreatic Aden... | AGX101 | 18 Years - | Angiex, Inc. | |
| Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy | NCT04225858 | Breast Cancer Triple Negative... HER2-positive B... Sentinel Lymph ... | Omission of sen... | 18 Years - | The Netherlands Cancer Institute | |
| A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | NCT03777579 | Triple Negative... | JS001，an engine... Nab-Paclitaxel Placebo | 18 Years - 70 Years | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | NCT02427581 | Triple Negative... Triple Negative... Triple-Negative... | Personalized sy... Poly ICLC | 18 Years - | Washington University School of Medicine | |
| VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study | NCT06409221 | Cancer, Breast Triple Negative... Early-stage Bre... | Non-interventio... | 18 Years - | Concr | |
| CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) | NCT02580448 | Cancer of the B... Breast Cancer Advanced Breast... Metastatic Brea... Male Breast Can... Triple Negative... ER+ Breast Canc... | Seviteronel | 18 Years - | Innocrin Pharmaceutical | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery | NCT06281210 | Breast Cancer Triple Negative... HER2-positive B... Neoadjuvant Che... | Omission of sur... | 18 Years - | European Institute of Oncology | |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. | NCT05340413 | HER2-negative B... Metastatic Brea... Triple Negative... | Olaparib | 18 Years - | SOLTI Breast Cancer Research Group | |
| Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | NCT02616848 | Triple Negative... | Everolimus Eribulin | 18 Years - | Istituti Ospitalieri di Cremona | |
| Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | NCT02768701 | Triple Negative... | Pembrolizumab Cyclophosphamid... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | NCT02595138 | Triple Negative... | Zoledronic acid | 18 Years - | ChineseAMS | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | NCT03310957 | Triple Negative... | ladiratuzumab v... Pembrolizumab | 18 Years - | Seagen Inc. | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
| First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) | NCT03401385 | Hormone Recepto... Triple Negative... Non-small Cell ... | Datopotamab Der... Steroid Contain... Non-Steroid Con... | 18 Years - | Daiichi Sankyo | |
| Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | NCT04443348 | Triple Negative... Hormone Recepto... Biopsy-proven, ... | Radiation Thera... Pembrolizumab Paclitaxel Carboplatin Cyclophosphamid... Doxorubicin Capecitabine | 18 Years - | Massachusetts General Hospital | |
| A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer | NCT06279364 | Triple Negative... | SKB264 Paclitaxel Nab-paclitaxel Capecitabine Eribulin Carboplatin | 18 Years - 75 Years | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | NCT03292172 | Advanced Ovaria... Triple Negative... | Atezolizumab RO6870810 | 18 Years - | Hoffmann-La Roche | |
| Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer | NCT03586297 | Triple Negative... | 18 Years - | Hackensack Meridian Health | ||
| Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer | NCT03150576 | Breast Cancer | Olaparib Paclitaxel and ... | 16 Years - 70 Years | Cambridge University Hospitals NHS Foundation Trust | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| S 81694 Plus Paclitaxel in Metastatic Breast Cancer | NCT03411161 | Metastatic Brea... Metastatic Trip... | Combination the... Paclitaxel Combination the... | 18 Years - | Servier | |
| RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | NCT02003092 | Solid Tumor Triple Negative... | RX-5902 | 18 Years - | Rexahn Pharmaceuticals, Inc. | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | NCT03970382 | Solid Tumor | NeoTCR-P1 adopt... nivolumab IL-2 | 18 Years - | PACT Pharma, Inc. | |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors | NCT06078670 | Advanced Solid ... | CVL218 | 18 Years - 75 Years | Fujian Cancer Hospital | |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | NCT05848739 | Breast Cancer M... Pancreatic Canc... NSCLC, Metastat... Synovial Sarcom... Colon Cancer Metastatic Colo... Melanoma Recurr... Metastatic Skin... Melanoma Stage ... Triple Negative... TNBC - Triple-N... Cholangiocarcin... Ovarian Cancer Metastatic Mela... Hepatocellular ... | ST316 | 18 Years - | Sapience Therapeutics | |
| Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET) | NCT06182306 | Breast Cancer Triple Negative... | Biopsy | 18 Years - | Ourotech, Inc. | |
| Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) | NCT03167619 | Triple Negative... | Olaparib Oral P... Olaparib Oral P... | 21 Years - | Duke University | |
| A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT) | NCT06351332 | Breast Cancer Breast Cancer F... Triple Negative... Hormone Recepto... HER2-negative B... | Azenosertib Carboplatin Pembrolizumab | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes | NCT01910844 | Metastatic Brea... | Cisplatin Cyclophosphamid... | 18 Years - | Centre Jean Perrin | |
| Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study | NCT04913571 | Triple Negative... | Eribulin Tislelizumab | 18 Years - 70 Years | Fudan University | |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | NCT03343613 | Solid Tumor Non Small Cell ... Renal Cell Carc... Triple Negative... | LY3381916 LY3300054 | 18 Years - | Eli Lilly and Company | |
| Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | NCT02681562 | Breast Cancer Triple Negative... | olaparib | 18 Years - 75 Years | Istituti Ospitalieri di Cremona | |
| A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | NCT01272141 | Breast Neoplasm... Breast Cancer Cancer of the B... | Lapatinib and E... | 18 Years - | Emory University | |
| Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | NCT05300958 | Triple Negative... | Deferoxamine Pl... | 18 Years - 70 Years | Sun Yat-sen University | |
| Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients | NCT06353997 | Triple Negative... | Pembrolizumab INBRX-106 | 18 Years - | Providence Health & Services | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Personalized Vaccine for Cancer Immunotherapy | NCT04879888 | Breast Cancer F... | Peptide pulsed ... | 18 Years - 65 Years | Universidad Nacional de Colombia | |
| TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | NCT03193853 | Triple Negative... | Tak-228 & Tak-1... Cisplatin & Nab... | 18 Years - | Baylor Research Institute | |
| Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss | NCT04251533 | Triple Negative... | alpelisib placebo nab-paclitaxel | 18 Years - | Novartis | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | NCT03945604 | Triple Negative... | SHR-1210 + Apat... | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer | NCT03362060 | Triple Negative... Metastatic Brea... | Pembrolizumab PVX-410 | 18 Years - | Massachusetts General Hospital | |
| Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | NCT05485766 | Triple Negative... Triple Negative... Breast Neoplasm... Breast Cancer BRCA1 Mutation BRCA2 Mutation BRCA Mutation BRCA-Associated... | Pembrolizumab Paclitaxel Carboplatin Olaparib Definitive Surg... | 18 Years - | Okayama University | |
| ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) | NCT02546934 | Breast Cancer | ABX, cisplatin Gemcitabine, Ci... | 18 Years - 70 Years | Fudan University | |
| Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | NCT04676997 | Triple Negative... | Camrelizumab Nab paclitaxel Epirubicin Cyclophosphamid... | 18 Years - 70 Years | Shandong Cancer Hospital and Institute | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer | NCT03740893 | Breast Neoplasm | AZD6738 Olaparib Durvalumab | 18 Years - | Institute of Cancer Research, United Kingdom | |
| GEN1046 Safety Trial in Patients With Malignant Solid Tumors | NCT03917381 | Solid Tumors Non-small Cell ... Urothelial Carc... Endometrial Car... Triple Negative... Squamous Cell C... Cervical Cancer | Acasunlimab Acasunlimab in ... Acasunlimab in ... Acasunlimab in ... | 18 Years - | Genmab | |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | NCT05451849 | Mesothelioma Mesotheliomas P... Mesothelioma, M... Mesothelioma Pe... Ovarian Cancer Ovarian Serous ... Pancreatic Canc... Pancreatic Aden... Colorectal Canc... Triple Negative... TNBC - Triple-N... Ovarian Adenoca... Pancreatic Neop... Colorectal Neop... Ovarian Neoplas... Cholangiocarcin... Non Small Cell ... | TC-510 Fludarabine Cyclophosphamid... | 18 Years - | TCR2 Therapeutics | |
| Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer | NCT03358017 | Triple Negative... | Zoledronate Atorvastatin 80... Standard neoadj... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | NCT03891953 | Carcinoma, Non-... Melanoma Nasopharyngeal ... Microsatellite ... Triple Negative... | DKY709 PDR001 | 18 Years - | Novartis | |
| Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients | NCT06225284 | Triple Negative... Premenopausal B... | Goserelin Aceta... | 18 Years - 50 Years | National Taiwan University Hospital | |
| RAPA-201 Therapy of Solid Tumors | NCT05144698 | Solid Tumor Breast Cancer Small Cell and ... Triple Negative... Gastric Cancer Esophageal Aden... Gastric Junctio... Esophageal Squa... Head and Neck C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Carcinoma of Un... Bladder Cancer Malignant Melan... | RAPA-201 Rapamy... Chemotherapy Pr... | 18 Years - | Rapa Therapeutics LLC | |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | NCT03387085 | Triple Negative... | Aldoxorubicin H... N-803 ETBX-011 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK for Infusi... avelumab bevacizumab Capecitabine Cisplatin Cyclophosphamid... 5-Fluorouracil Leucovorin nab-Paclitaxel SBRT | 18 Years - | ImmunityBio, Inc. | |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | NCT04260802 | Cancer Neoplasms Metastatic Canc... Triple Negative... Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular ... Squamous Cell C... Urothelial Carc... Urothelial Neop... Non Small Cell ... Renal Cell Carc... Locally Advance... Locally Advance... Squamous Cell C... Sarcoma Merkel Cell Car... Bladder Cancer | OC-001 OC-001 in Combi... | 18 Years - | Ocellaris Pharma, Inc. | |
| Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer | NCT02635672 | Neoplasms | VIP152 (BAY 125... VIP152 (BAY 125... Keytruda VIP152 (BAY 125... | 18 Years - | Vincerx Pharma, Inc. | |
| Sitravatinib in Metastatic Breast Cancer | NCT04123704 | Breast Cancer S... Triple Negative... Breast Neoplasm... Breast Cancer M... | Sitravatinib | 18 Years - | Baylor Breast Care Center | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | NCT03449108 | Bone Sarcoma Dedifferentiate... Giant Cell Tumo... Malignancy in G... Malignant Solid... Ovarian Carcino... Platinum-Resist... Poorly Differen... Recurrent Osteo... Recurrent Ovari... Refractory Oste... Soft Tissue Sar... Thyroid Gland A... Thyroid Gland S... Undifferentiate... Triple Negative... | Aldesleukin Autologous Tumo... Autologous Tumo... Cyclophosphamid... Fludarabine Ipilimumab Nivolumab Quality-of-Life... Questionnaire A... | 16 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors | NCT02644369 | Squamous Cell C... Triple Negative... Epithelial Ovar... Malignant Melan... Advanced Solid ... | Pembrolizumab | 18 Years - | University Health Network, Toronto | |
| Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | NCT02511847 | Triple Negative... | Afatinib | 20 Years - | National Taiwan University Hospital | |
| AMT-151 in Patients With Selected Advanced Solid Tumours | NCT05498597 | Advanced Solid ... Advanced Cancer Advanced Carcin... Ovarian Cancer Ovarian Carcino... Ovarian Epithel... Ovarian Endomet... Endometrial Can... Endometrial Ade... Endometrial Ser... Endometrial End... Endometrial Cle... Lung Adenocarci... Triple Negative... Pancreatic Duct... Malignant Pleur... Ovarian Clear C... Ovarian Clear C... Ovarian Mucinou... | AMT-151 | 18 Years - | Multitude Therapeutics Inc. | |
| Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | NCT05909332 | Breast Cancer Triple Negative... | Antivascular th... Chemotherapy | 18 Years - 70 Years | Fudan University | |
| GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | NCT01918306 | Estrogen Recept... Human Epidermal... Triple Negative... Recurrent Breas... Stage IV Breast... Triple-negative... | cisplatin laboratory biom... pharmacological... dynamic contras... GDC -0941 | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment | NCT05404321 | Triple Negative... Organoid | Establishment o... | 18 Years - | Centre Francois Baclesse | |
| Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer | NCT04837209 | Breast Cancer Triple Negative... | Niraparib Dostarlimab Radiation thera... | 18 Years - | Massachusetts General Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
